Business
AGM results
AGM results.
About this update from Genedrive Plc
[{"type":"text","content":"\n RNS Number : 9121W Epistem Holdings plc 26 November 2010 \n\n \n \nEpistem Holdings Plc\n \n26th November 2010\n \nEpistem Plc (LSE: EHP), the rapidly growing UK biotechnology and Personalised Medicine company announces today that all resolutions at the Annual General Meeting held on 24 November 2010 were passed. \n \n \n \n \n\n\n\n\nEpistem Plc\n\n\n\n\n\n\n\n\n\n\nMatthew Walls \n\n\nChief Executive Officer\n\n\n+44 (0) 161 606 7258\n\n\n\n\nJohn Rylands \n\n\nFinance Director\n\n\n+44 (0) 161 606 7258\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKBC Peel Hunt Ltd\n\n\n\n\n\n\n\n\n\n\nJames Steel\n\n\n\n\n\n+44 (0) 207 418 8900\n\n\n\n\nVijay Barathan\n\n\n\n\n\n+44 (0) 207 418 8900\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDe Facto Communications\n\n\n\n\n\n\n\n\n\n\nMike Wort / Anna Dunphy\n\n\n\n\n\n+44 (0) 20 7861 3838\n\n\n\n\n \n \n \nNotes to Editors: \n \nAbout Epistem \nEpistem is a biotechnology and Personalised Medicine company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases and dermatological applications. Epistem develops innovative therapeutics, biomarkers and diagnostics and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. The Company was originally formed in 2000 and this year celebrates its 10 year anniversary. \n \nEpistem operates three distinct business divisions, Contract Research Services, Novel Therapies and Personalised Medicine (biomarker and diagnostics). \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END RAGUNSVRRBAAUAA \n ","length":5473,"tagName":"div"}]